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Summary
Background: We conducted a prospective, multicenter observational cohort study in Thailand to
characterize the epidemiology of extrapulmonary tuberculosis (TB) in HIV-infected persons and to
identify risk factors for death.
Methods: From May 2005 to September 2006, we enrolled, interviewed, examined, and per-
formed laboratory tests on HIV-infected adult TB patients and followed them from TB treatment
initiation until the end of TB treatment. We conducted multivariate proportional hazards analysis
to identify factors associated with death.
Results: Of the 769 patients, pulmonary TB only was diagnosed in 461 (60%), both pulmonary and
extrapulmonary TB in 78 (10%), extrapulmonary TB at one site in 223 (29%), and extrapulmonary
TB at more than one site in seven (1%) patients. Death during TB treatment occurred in 59 of 308
patients (19%) with any extrapulmonary involvement. In a proportional hazards model, patients
with extrapulmonary TB had an increased risk of death if they had meningitis, and a CD4+
T-lymphocyte count <200 cells/ml. Patients who received co-trimoxazole, fluconazole, and
antiretroviral therapy during TB treatment had a lower risk of death.
* Corresponding author. Tel.: +66 580 0669; fax: +66 591 2909.
E-mail address: wanitchayak@th.cdc.gov (W. Kittikraisak).
1201-9712/$36.00. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.11.013
Conclusions: Among HIV-infected patients with TB, extrapulmonary disease occurred in 40% of the
patients, particularly in those with advanced immune suppression. Death during TB treatment was
common, but the risk of death was reduced in patients who took co-trimoxazole, fluconazole, and
antiretroviral therapy.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Tuberculosis (TB) is a major global public health problem,
causing almost nine million illnesses and two million deaths
each year.1 In adults with normal immune systems, TB disease
is usually confined to the lungs, but in persons with immune
suppression, such as HIV infection, Mycobacterium tubercu-
losis (MTB) bacilli frequently disseminatebeyond the lungs and
cause disease in other organ systems.2 Although most TB
programs focus on the control of infectious pulmonary TB,
about one in five TB cases worldwide is considered extrapul-
monary, which is defined as TB disease occurring outside the
lung parenchyma.1,3 In the past 20 years, countries with HIV
epidemicshave seenadramatic increase in extrapulmonaryTB
casesanddeaths; themostcommon sites ofdisease includethe
lymph nodes, meninges, pericardium, peritoneal cavity, and
intra-abdominal organs.4—11 Mortality in HIV-associated extra-
pulmonary TB is high, ascribed to a combination of advanced
HIV disease, concomitant opportunistic infections, and
delayed diagnosis and treatment of TB.12
Thailand is one of 22 World Health Organization (WHO)-
designated high burden TB countries, with an estimated
annual TB incidence of 142 per 100 000 population and TB
mortality rate of 19 per 100 000 population.1 An estimated
15—20% of all TB cases occur in HIV-infected persons.13 Of all
TB cases reported nationally from 2002 to 2005, extrapul-
monary disease accounted consistently for 12—13%, but high
HIV prevalence provinces reported that the percentage of
extrapulmonary TB cases was as high as 33%.14,15 Although
national statistics for outcome of extrapulmonary TB treat-
ment are not routinely monitored, the mortality rate is
believed to be high. We conducted a prospective, multi-
center observational cohort study in Thailand to characterize
the epidemiology of extrapulmonary TB in HIV-infected per-
sons and to identify risk factors for death.
Methods
Study population and setting
From May 2005 to September 2006, we recruited patients
from the national infectious diseases referral hospital (Bam-
rasnaradura Infectious Diseases Institute) and public TB
treatment facilities in Ubon Ratchathani, Phuket, and Bang-
kok provinces into a prospective, observational cohort study.
The study population included HIV-infected adults diagnosed
with active TB disease and receiving anti-TB therapy accord-
ing to the national TB program guidelines for less than four
weeks before study enrollment.16 We excluded prisoners and
pregnant women. For this study, we did not perform any
health-related interventions; patients received usual care
for TB, HIV, and other diseases. This study was approved by
the ethical review committees of the Bangkok MetropolitanAdministration, the Thailand Ministry of Public Health, and
the US Centers for Disease Control and Prevention.
Data collection and laboratory studies
Patients had three study visits: at the beginning of TB
treatment, at the end of the intensive phase of TB treat-
ment (usually two months into treatment), and at the end
of TB treatment (usually six months after treatment initia-
tion). At the beginning of treatment, patients were inter-
viewed using standardized study forms that asked about
demographic characteristics, past and present medical
history, knowledge and attitudes related to TB and HIV,
and sex and drug use history. At every study visit, patients
received a physical examination and provided information
about medications taken and any adverse events experi-
enced since their previous visit. Study staff reviewed med-
ical records for any health-related problem that occurred
between study visits.
At the beginning of treatment, blood sampleswere tested
for liver function enzymes, complete blood count, viral
hepatitis serology, and CD4+ T-lymphocyte (CD4) count.
Sputum and specimens from extrapulmonary sites were
collected for acid-fast bacilli smear and for mycobacterial
culture using solid and liquid media, identification, and
drug-susceptibility testing. Not all patients with sputum
smears had culture results available for analysis, because
culture was not performed or the culture grew nothing, a
contaminant, or non-tuberculous mycobacteria. Study
nurses recorded the locations in which TB was diagnosed.
We classified patients as having ‘disseminated’ TB if extra-
pulmonary TB was diagnosed in more than one extrapulmon-
ary organ system (e.g., osteoarticular and liver) or
pulmonary TB was diagnosed together with any type of
extrapulmonary TB.
We assessed outcomes at the end of TB treatment accord-
ing to WHO guidelines; successful TB treatment comprised
both cured and completed treatment.16 For patients
recorded as defaulting during TB treatment, we reviewed
the government’s vital status registry to determine whether
patients died within 90 days of defaulting; such patients were
re-classified as deaths during TB treatment.
Statistical analysis
We calculated proportions for the description of demographic
characteristics and clinical features. We examined the rela-
tionship between CD4 levels and anatomic location of TB
disease. A one-way Kruskal—Wallis test was performed to
determine if the CD4 level across the sites significantly
differed. Using pulmonary TB as a referent group, a regres-
sion with dummy variables was then fitted on log CD4 levels to
determine groups that were different from the referent
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classified patients with both pulmonary and extrapulmonary
TB as having extrapulmonary TB. We then performed uni-
variate logistic regression analyses. We tested covariates
that were significant at p  0.20 for collinearity and con-
structed multivariate logistic regression models of all
patients and of bacteriologic-confirmed TB patients (at least
one specimen collected at any time before or during treat-
ment was positive for acid-fast bacilli and/or culture-positive
for MTB). Two-way interaction terms were generated as
products of covariates and also entered into models. For this
analysis and all other multivariate analyses, we fitted parsi-
monious models by using a backward stepwise procedure and
assessed model fitness using the Hosmer—Lemeshow good-
ness-of-fit test. We also examined factors associated with
death in patients with different locations of extrapulmonary
TB, using pulmonary TB patients as the referent group. For
this analysis, we calculated time from TB treatment initia-
tion to treatment completion or death, confirmed that the
proportional hazards model assumption was met, and then
constructed a multivariate Cox proportional hazards model.
We included in the model factors that were associated with
death at p  0.20 in univariate analyses for all patients and,
because of small sample size, excluded patients with less
common forms of extrapulmonary TB (16 pleural, four cuta-
neous, three osteoarticular, and three pericardial TB patients
excluded). For this analysis, we did not fit a model for
bacteriologic-confirmed TB patients because the small num-
ber made our model unstable.
A two-sided p-value of 0.05 was used to indicate statis-
tical significance. We performed all analyses using Stata
software version 8.0 (StataCorp LP, College Station, TX, USA).Figure 1 Enrollment of HResults
Enrollment and characteristics of patients
Of 1096 eligible patients, we enrolled 849 (78%) and, after
excluding cases whose diagnosis changed, analyzed 769
(Figure 1). The median length from TB treatment initiation
to study enrollment was seven days (interquartile range
(IQR) 1—8 days). Of the 769 patients, pulmonary TB only
was diagnosed in 461 (60%), both pulmonary and extrapul-
monary TB in 78 (10%), extrapulmonary TB at one site in 223
(29%), and extrapulmonary TB at more than one site in seven
(1%) patients. Of the 223 patients with extrapulmonary TB at
one site, 139 (62%) had lymphatic, 29 (13%) meningeal, 29
(13%) intra-abdominal, 16 (7%) pleural, four (2%) cutaneous,
three (1%) osteoarticular, and three (1%) pericardial TB.
Bacteriologic confirmation was documented in 410 (76%)
patients who had at least pulmonary TB (includes those
who also had extrapulmonary TB) and 121 (53%) patients
with extrapulmonary TB; culture confirmation occurred in
333 (62%) and 80 (35%), respectively. Of the 413 culture-
confirmed TB patients, 23 (6%) were multidrug-resistant TB,
39 (9%) were isoniazid-resistant TB, and five (1%) were
rifampin-resistant TB.
Table 1 displays patient characteristics stratified by type
of TB. At the end of follow-up, 493 (64%) patients were
successfully treated, six (1%) failed treatment, 134 (17%)
died, 61 (8%) defaulted, 70 (9%) transferred out, and five (1%)
were still on treatment. Death during TB treatment occurred
in 43/230 (19%) patients with exclusively extrapulmonary TB
(including extrapulmonary at 1 site) and 59/308 (19%)
patients with any extrapulmonary involvement. When stra-IV-infected TB patients.
Table 1 Characteristics, clinical features at time of TB diagnosis, and treatment outcomes among HIV-infected TB patients,
stratified by disease classification
All (N = 769) Pulmonary
TB only
(N = 461)
Extrapulmonary
at 1 site
(N = 230)
Both pulmonary and
extrapulmonary TB
(N = 78)
Characteristics
Age >34 years 380 (49) 233 (50) 111 (48) 36 (46)
Male 538 (70) 347 (75) 139 (60) 52 (67)
Finished 6th grade education 300 (39) 178 (39) 95 (41) 27 (35)
CD4 <200 cells/mla 608 (81) 345 (77) 192 (85) 71 (92)
Timing of HIV diagnosis in relation to TB diagnosis
Same year 495 (64) 329 (71) 120 (52) 46 (59)
1—5 years prior 190 (25) 96 (21) 77 (33) 17 (22)
6—10 years prior 57 (7) 25 (5) 21 (9) 11 (14)
>10 years prior 15 (2) 3 (1) 8 (3) 4 (5)
Hospitalized at enrollment 205 (27) 93 (20) 81 (35) 31 (40)
Delay in HIV diagnosisa,b 359 (72) 235 (69) 87 (76) 37 (82)
Delay in TB diagnosisc 371 (48) 248 (54) 86 (37) 37 (47)
Previously had lymphoma 10 (1) 3 (1) 6 (3) 1 (1)
Registered as new case 667 (87) 387 (84) 206 (90) 74 (95)
Know anyone with TB 283 (37) 172 (37) 84 (36) 27 (35)
Medications taken during TB treatment
2HRZE/4HR regimen 665 (86) 378 (82) 217 (94) 70 (90)
Co-trimoxazoled 635 (82) 369 (80) 200 (87) 66 (85)
Fluconazoled 434 (56) 241 (52) 148 (64) 45 (58)
Antiretrovirald 307 (40) 156 (34) 126 (55) 25 (32)
Physical examination
Body mass index <18.5 kg/m2 443 (58) 276 (60) 117 (51) 50 (64)
HBsAg reactive 70 (9) 42 (9) 21 (9) 7 (9)
Anti-HCV reactive 237 (31) 167 (36) 42 (18) 28 (36)
HBsAg and anti-HCV reactive 27 (3) 21 (4) 5 (2) 1 (1)
Albumin <2.5 g/dl 164 (21) 82 (18) 52 (23) 30 (38)
Treatment outcomes
Cure/complete 493 (64) 301 (65) 151 (66) 41 (52)
Failure 6 (1) 5 (1) 1 (0) 0 (0)
Died 134 (17) 75 (16) 43 (19) 16 (20)
Default 61 (8) 39 (8) 14 (6) 8 (10)
Transfer out 70 (9) 37 (8) 20 (9) 13 (17)
On treatment 5 (1) 4 (1) 1 (0) 0 (0)
Results are n (%).
TB, tuberculosis; CD4, CD4+ T-lymphocyte; 2HRZE/4HR, two months of rifampin, isoniazid, pyrazinamide, and ethambutol followed by four
months of rifampin and isoniazid; HBsAg, hepatitis B surface antigen; anti-HCV, hepatitis C antibodies.
a Those with available results only.
b Patients were considered to have a delay in HIV diagnosis if their CD4+ T-lymphocyte count at the time of HIV diagnosis was
<200 cells/ml; standard assumptions were used to estimate CD4+ T-lymphocyte count at the time of HIV diagnosis for patients with a
pre-existing HIV diagnosis, no CD4+ T-lymphocyte count recorded at the time of HIV diagnosis, and no history of ART treatment.
c Patients were considered to have a delay in TB diagnosis if they reported: (a) having a cough lasting greater than one
month before TB diagnosis; or (b) having other symptoms that lasted longer than 14 days and self-assessed these symptoms as being
severe.
d Those starting opportunistic infection prophylaxis and antiretroviral medicines within 30 days of TB treatment completion were classified
as not receiving these medicines.
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pulmonary only, 20/139 (14%) lymphatic, 11/29 (38%) menin-
geal, 10/29 (34%) intra-abdominal, 1/16 (6%) pleural, 16/85
(19%) disseminated, 1/4 (25%) cutaneous, 0/3 (0%) osteoar-
ticular, and 0/3 (0%) pericardial TB cases.Anti-TB treatment and duration
The standard anti-TB regimen including two months of rifam-
pin, isoniazid, pyrazinamide, and ethambutol followed by
four months of rifampin and isoniazid was prescribed in 378/
Figure 2 CD4+ T-lymphocyte count and prevalence of extra-
pulmonary TB among HIV-infected TB patients (number of
patients is shown at the top of each bar; patients with both
pulmonary and extrapulmonary TB were classified as having
extrapulmonary TB).
726 N. Kingkaew et al.461 (82%) patients diagnosed with pulmonary TB only, 70/78
(90%) patients with pulmonary and extrapulmonary TB, and
217/230 (94%) patients with extrapulmonary TB at 1 site.
Directly observed therapy by healthcare workers or village
health volunteers was offered to all patients; 246 (32%) opted
to participate. The median duration of TB treatment among
patients with pulmonary TB only was 190 (IQR 159—249) days,
in patients with pulmonary and extrapulmonary TB was 204
(IQR 161—272) days, and in patients with extrapulmonary TB
at 1 site was 192.5 (IQR 122—237) days. Most patients
reported having an array of symptoms at two months into
TB treatment. The most common symptom was itching rash
(reported by 45% of the patients), followed by fatigue (41%)
and pain in muscles or joints (35%).
Extent of immunosuppression and clinical
manifestation of TB disease
Figure 2 shows the percentage of patients with extrapulmon-
ary TB according to CD4 count. As CD4 decreased from over
400 cells/ml to 200 cells/ml, the percentage of TB patients
with extrapulmonary TB increased from 19% to 35%. The
percentage of extrapulmonary involvement was relatively
stable when CD4 dropped below 200 cells/ml. Osteoarticular
TB was the most common location of disease among patients
with high levels of CD4 (Table 2). Pleural TB occurred at a
significantly higher CD4 than pulmonary TB; intra-abdominal,
lymphatic, and disseminated at a significantly lower CD4.
Risk factors for extrapulmonary TB
In multivariate logistic regression analysis of all patients,
factors associated with extrapulmonary TB included being
hospitalized at enrollment (adjusted odds ratio (AOR) 1.6,
95% confidence interval (CI) 1.1—2.3), treated for TB at the
national infectious diseases institute (AOR 2.3, 95% CI 1.6—
3.4), having been diagnosed with HIV 1—5 years (AOR 1.7, 95%
CI 1.2—2.6) and >10 years before TB diagnosis (AOR 7.3, 95%
CI 1.8—29.1), and having been previously diagnosed with
lymphoma (AOR 4.5, 95% CI 1.1—18.4) (Table 3). Extrapul-
monary TB was less likely to occur in patients who were male
(AOR 0.7, 95% CI 0.5—1.0), had hepatitis C antibodies (AOR
0.6, 95% CI 0.4—0.9), and had a CD4 count>199 cells/ml (AORTable 2 Primary location of TB disease and CD4+ T-lymphocyte l
Primary location
of TB disease
No. of
patients
No. (%) of patients
with CD4 <100 cells/ml
Osteoarticular 3 1 (33)
Pleural 16 4 (25)
Meningeal 29 17 (59)
Cutaneous 4 2 (50)
Pulmonary 451 273 (60)
Lymphatic 138 98 (71)
Pericardial 3 2 (67)
Disseminatedb 84 63 (75)
Intra-abdominal 28 23 (82)
TB, tuberculosis; CD4, CD4+ T-lymphocyte; Ref., referent group.
a Only patients with available CD4+ T-lymphocyte counts.
b Patients diagnosed with TB in >1 extrapulmonary organ system or p0.6, 95% CI 0.4—1.0). In a subset of bacteriologic-confirmed
patients, risk factors remaining significantly associated with
extrapulmonary TB were being hospitalized at enrollment,
treated for TB at the national infectious diseases institute,
and having been diagnosed with HIV >10 years before TB
diagnosis. Having hepatitis C antibodies remained protective
for extrapulmonary TB.
Risk factors for death
In a proportional hazards model of all patients, we found a
significant association between location of extrapulmonary
TB and death. Meningeal TB patients died at greater rates
compared to pulmonary TB patients (hazard ratio (HR) 3.5,
95% CI 1.2—9.9) (Table 4). Other factors associated with
higher risk of death were having a CD4 count 0—24 cells/
ml (HR 10.2, 95% CI 4.4—24.0), having a CD4 count 25—
99 cells/ml (HR 4.1, 95% CI 1.7—9.6), having a CD4 count
100—199 cells/ml (HR 4.0, 95% CI 1.5—10.7), and being hos-
pitalized at enrollment (HR 2.9, 95% CI 1.7—4.7). Co-trimox-
azole (HR 0.5, 95% CI 0.3—1.0), fluconazole (HR 0.5, 95% CIevel among HIV-infected TB patientsa
Median CD4
(cells/ml)
Interquartile range
of CD4 (cells/ml)
p
268 4—592 0.69
145 101—209 0.02
84 50—153 0.48
77 22—217 0.38
71 26—191 Ref.
49 22—129 0.02
48 37—110 0.91
42 15—101 <0.01
37 15—65 <0.01
atients with both pulmonary and any type of extrapulmonary TB.
Table 3 Univariate and multivariate logistic regression ana-
lyses of risk factors for having extrapulmonary TB among HIV-
infected TB patients
Characteristics OR (95% CI) AOR (95% CI)
Sex
Male 0.5 (0.4—0.7) 0.7 (0.5—1.0)
Female Ref. Ref.
Treated for TB at national infectious diseases institute
Yes 3.2 (2.3—4.4) 2.3 (1.6—3.4)
No Ref. Ref.
Hospitalized at enrollment
Yes 2.3 (1.6—3.1) 1.6 (1.1—2.3)
No Ref. Ref.
Timing of HIV diagnosis in relation to TB
Same year Ref. Ref.
1—5 years prior 1.9 (1.4—2.7) 1.7 (1.2—2.6)
6—10 years prior 2.1 (1.3—3.5) 1.5 (0.9—2.7)
>10 years prior 7.9 (2.2—28.5) 7.3 (1.8—29.1)
Previous diagnosis of lymphoma
Yes 3.5 (0.9—13.8) 4.5 (1.1—18.4)
No Ref. Ref.
Hepatitis C antibodies reactive
Yes 0.5 (0.4—0.7) 0.6 (0.4—0.9)
No Ref. Ref.
Registered as new case
Yes 1.9 (1.2—3.0) 1.8 (1.0—3.0)
No Ref. Ref.
CD4+ T-lymphocyte count (cells/ml)
0—24 Ref. Ref.
25—99 0.9 (0.6—1.3) 0.9 (0.6—1.3)
100—199 0.9 (0.6—1.4) 1.0 (0.6—1.6)
>199 0.5 (0.3—0.8) 0.6 (0.4—1.0)
TB, tuberculosis; OR, odds ratio; AOR, adjusted odds ratio; CI,
confidence interval; Ref., referent group.
Table 4 Multivariate Cox proportional hazards analysis of
risk factors for death among HIV-infected extrapulmonary TB
patientsa
Factors HR 95% CI p
Lower Upper
CD4+ T-lymphocyte count (cells/ml)
0—24 10.2 4.4 24.0 <0.01
25—99 4.1 1.7 9.6 <0.01
100—199 4.0 1.5 10.7 <0.01
>199 Ref.
Hospitalized at enrollment
Yes 2.9 1.7 4.7 <0.01
No Ref.
Received co-trimoxazole during TB treatmentb
Yes 0.5 0.3 1.0 0.05
No Ref.
Received fluconazole during TB treatmentb
Yes 0.5 0.3 0.9 0.01
No Ref.
Received ART during TB treatmentb
Yes 0.2 0.1 0.3 <0.01
No Ref.
Platelet level at enrollment 150  109 cells/l
Yes 1.0 0.5 2.0 0.91
No Ref.
Type of extrapulmonary TB
Intra-abdominal 0.7 0.1 3.0 0.59
Disseminated 0.6 0.3 1.3 0.22
Meningeal 3.5 1.2 9.9 0.02
Lymphatic 0.7 0.3 1.5 0.37
Pulmonary Ref.
TB, tuberculosis; HR, hazard ratio; CI, confidence interval; ART,
antiretroviral therapy; Ref., referent group.
a Patients starting opportunistic infection prophylaxis and anti-
retroviral medicines before TB treatment initiation were
excluded.
b Those starting opportunistic infection prophylaxis and anti-
retroviral medicines within 30 days of TB treatment completion
were classified as not receiving these medicines.
HIV and extrapulmonary TB, Thailand 7270.3—0.9), and antiretroviral (ART) use (HR 0.2, 95% CI 0.1—
0.3) were associated with a lower risk of death. Among
patients receiving ART during TB treatment, the most com-
mon regimen was a nevirapine-containing regimen, followed
by an efavirenz-containing regimen.
Discussion
Among HIV-infected patients with TB, extrapulmonary dis-
ease occurred in 40% of the patients, particularly in those
with advanced immune suppression. Death during TB treat-
ment was common, but the risk of death was reduced in
patients taking co-trimoxazole, fluconazole, and ART.
Consistent with previous studies, we found that advanced
HIV was strongly correlated with the occurrence of extra-
pulmonary TB.8 The major risk factors for extrapulmonary TB
in our study were low CD4 level, first HIV diagnosis more than
one year before TB diagnosis, and lymphoma, a malignancy
that may be HIV-associated. Of note, the relationship
between CD4 level and extrapulmonary involvement was
not absolute; the median CD4 count for pleural TB patientswas significantly higher than that of pulmonary TB patients,
and there was trend toward a higher CD4 count for osteoar-
ticular and meningeal TB patients. Pleural TB is more com-
mon in HIV-uninfected persons and may be more common
among HIV-infected persons with high CD4 counts, because
TB pleural effusions are usually caused by delayed type
hypersensitivity to mycobacterial antigens.17 The reason
for a possible association between high CD4 count and
osteoarticular or meningeal TB, however, are not as clear.
We also found a relationship between extrapulmonary TB and
female sex, a relationship hypothesized in other studies to be
due to differential exposure of women to infectious TB
patients, smoking, and medical care compared with
men.4—6,18—24
Pulmonary TB in HIV-infected patients is frequently spu-
tum smear-negative, making diagnosis challenging and
increasing the possibility that TB disease will disseminate
728 N. Kingkaew et al.outside the lungs.25 In 2006, WHO released guidelines to
improve diagnosis of smear-negative TB and extrapulmonary
TB in HIV-prevalent settings; simple, standardized guidelines
were provided for diagnosing peripheral lymph node, pleural,
pericardial, meningeal, and disseminated (miliary) TB based
on clinical findings.12 Because HIV-infected patients may
have multiple concomitant infections, microbiologic confir-
mation of clinical diagnosis is still important, even though we
found that it is not often done, as in other published
reports.26 Research is needed to develop less invasive and
more sensitive tools for diagnosing extrapulmonary TB.
In our study, we evaluated a large number of factors that
could increase the risk of death in patients with extrapul-
monary TB, including delays in TB and HIV diagnosis, social
and economic conditions, and concomitant illnesses. We
found that the strongest independent determinants of survi-
val were use of ART and opportunistic infection prophylaxis
during TB treatment. In several observational studies, ART
has been shown to be life-saving in HIV-associated TB.27—30
We do not know why some patients did not receive ART, even
though such care is widely available in Thailand and has been
demonstrated to improve survival. Possible reasons include
lack of physician knowledge about the benefits of early ART,
fear of immune reconstitution inflammatory syndrome or
drug toxicity, patient reluctance to take many pills, or other
health system barriers. One clinical trial and several obser-
vational studies have shown a similar benefit to co-trimox-
azole, and one previous observational study in Thailand has
shown a benefit to fluconazole.31—35 Our study is the only one
to have evaluated these interventions prospectively in HIV-
infected patients with extrapulmonary TB.17,36 In multivari-
ate analysis, the risk of death was not significantly greater for
patients with different sites of extrapulmonary TB compared
with pulmonary TB, except for meningeal TB, which had an
over 3-fold increased risk of death. Meningeal TB is particu-
larly challenging to diagnose, because cerebrospinal fluid is
frequently smear- and culture-negative.37 Regardless of HIV
infection, treatment outcomes are poor, requiring adjunctive
corticosteroids and early initiation and prolonged use of TB
treatment.38 At least one clinical trial is ongoing to evaluate
the added benefit of early ART in patients already receiving
optimum clinical care for meningeal TB.39
Our study is subject to several important limitations.
First, and most important, many patients did not have micro-
biologic confirmation of TB and were diagnosed based on a
constellation of clinical, laboratory, and radiographic find-
ings. We did not apply rigorous criteria for extrapulmonary
TB, because the study was aimed to describe the features of
patients routinely diagnosed and treated in the public health
system, where such criteria do not exist. To account for the
possibility of misclassification, we restricted some analyses
to only those patients with bacteriologic or culture confirma-
tion of MTB. The consistency of our findings among those with
microbiologic confirmation suggests that misdiagnosis,
although a common problem, would not explain the findings
of this study. Second, extrapulmonary TB refers to a hetero-
geneous group of pathological entities, each with unique
diagnostic and treatment challenges. Our sample size was
too small for us to evaluate some well-known types of
extrapulmonary TB (e.g., pleural, cutaneous, pericardial)
and to construct independent models for each type. Lastly,
there is a discrepancy between the proportion of smear-positive and the number of positive cultures, because cul-
tures were not performed, were contaminated, or did not
grow MTB for some patients.
In conclusion, we found that extrapulmonary TB occurred
predominantly in patients with advanced HIVand that appro-
priate HIV-related care and treatment was the single most
important determinant of survival in patients with extrapul-
monary TB. At a population level, improving survival will
require awareness of clinicians about the diverse manifesta-
tions of extrapulmonary TB in patients with AIDS, expanded
use of existing diagnostic tools, research into new diagnostic
tools, and universal access to HIV care and treatment.
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